Abstract 1470: Development & characterization of a new oncolytic immunotherapy platform based on herpes simplex virus type 1

@article{Thomas2019Abstract1D,
  title={Abstract 1470: Development & characterization of a new oncolytic immunotherapy platform based on herpes simplex virus type 1},
  author={S. Thomas and Linta Juncheria and Victoria Roulstone and J. Kyula and H. L. Kaufman and K. Harrington and R. Coffin},
  journal={Cancer Research},
  year={2019},
  volume={79},
  pages={1470-1470}
}
  • S. Thomas, Linta Juncheria, +4 authors R. Coffin
  • Published 2019
  • Medicine
  • Cancer Research
  • A number of oncolytic viruses have shown single agent clinical activity and evidence of clinical synergy with immune checkpoint blockade. However, not all patients respond, and as yet most of the promising clinical data have been generated in patients with melanoma. With the objective of maximally activating a patient9s immune system against their own cancer which will then provide enhanced synergy with anti-PD1/L1 blockade, we developed a new oncolytic immunotherapy platform based on herpes… CONTINUE READING